Notícias de Takeda Pharmaceutical

Últimas notícias

Manchetes no idioma original da fonte.

• 
  Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium (abre em uma nova aba)

  PR Newswire · 6 de out. de 2026

• Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run (abre em uma nova aba)

  1 de out. de 2026

• 
  Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal (abre em uma nova aba)

  1 de out. de 2026

• Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative (abre em uma nova aba)

  1 de out. de 2026

• Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data (abre em uma nova aba)

  30 de set. de 2026

• Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading (abre em uma nova aba)

  30 de set. de 2026

• Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial (abre em uma nova aba)

  30 de set. de 2026

• Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill (abre em uma nova aba)

  30 de set. de 2026

• KROS Begins Dosing in Phase II Study With Rinvatercept in DMD (abre em uma nova aba)

  29 de set. de 2026

• Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium (abre em uma nova aba)

  29 de set. de 2026

• Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC (abre em uma nova aba)

  28 de set. de 2026

• Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry (abre em uma nova aba)

  25 de set. de 2026

• Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 (abre em uma nova aba)

  22 de set. de 2026

• Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? (abre em uma nova aba)

  18 de set. de 2026

• Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems (abre em uma nova aba)

  18 de set. de 2026

• Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis? (abre em uma nova aba)

  17 de set. de 2026

• Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act? (abre em uma nova aba)

  16 de set. de 2026

• Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight (abre em uma nova aba)

  15 de set. de 2026

• Hummingbird Bioscience Appoints Dr. James Garner as President (abre em uma nova aba)

  15 de set. de 2026

• Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading (abre em uma nova aba)

  14 de set. de 2026

• 
  Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline (abre em uma nova aba)

  NYSE · 10 de ago. de 2026

• 
  Takeda and Indonesia partner on plasma-derived therapies (abre em uma nova aba)

  Pharmaceutical Technology · 13 de jul. de 2026

• 
  Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products (abre em uma nova aba)

  Business Wire · 12 de jul. de 2026

• 
  Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine (abre em uma nova aba)

  Benzinga · 5 de jul. de 2026

• 
  Takeda’s New AI Drug Discovery Deal With Insilico Might Change The Case For Investing In Takeda Pharmaceutical (TSE:4502) (abre em uma nova aba)

  Simply Wall St. · 3 de jul. de 2026

• 
  Insilico Medicine, Takeda partner on AI-driven drug discovery (abre em uma nova aba)

  Pharmaceutical Technology · 2 de jul. de 2026

• 
  Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery (abre em uma nova aba)

  PR Newswire · 2 de jul. de 2026

• 
  Mass.’ largest biotech employer swings to near $1B loss after Boston jury delivers major blow (abre em uma nova aba)

  MassLive · 20 de jun. de 2026

• 
  Boltz Announces Collaboration with Takeda to Deploy Frontier Biomolecular AI Models Across Takeda's Research Organization (abre em uma nova aba)

  PR Newswire · 18 de jun. de 2026

• 
  Takeda (TSE:4502) Unveils Phase 3 Wins In Narcolepsy And Psoriasis (abre em uma nova aba)

  Simply Wall St. · 16 de jun. de 2026